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Abstract 
Background: The mainstay treatment for eczema is leave-on emollients. The aim of this study was to 
find out more about unwanted effects that have been reported with their use, as little is known due to 
a lack of formal reporting. Aims: To gain a greater understanding of eczema patients’ experiences of 
unwanted effects such as stinging, what influence unwanted effects had on their therapy, why subsequent 
variations in leave-on emollient adherence followed and what patients desire in their emollients.  
Methods: An anonymous online survey was conducted among eczema patients and their carers in 
March 2016 (using SurveyMonkeyTM). Results: 210 respondents, including adults and young people with 
eczema plus carers of children with eczema, which included family and friends. 68% (n=126/185)  
reported a wide range of 38 unwanted effects. Accounts highlighted the impact on quality of life of these 
unwanted effects and variations to eczema management that followed.  71% (90/126) of respondents 
stopped a leave-on emollient due to unwanted effects. Desired characteristics in emollients related to 
the absence of unwanted effects and product improvements. Conclusion: Eczema patients and their 
carers all reported high levels of unwanted effects from leave-on emollient use. Experiences of  
unwanted effects were multifactorial but common themes arose as did the desire for emollient 
improvements. Unwanted effects need to be considered when optimising therapy.
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Introduction
Atopic eczema is a common disease 
that affects around 1 in 5 children and is 
indiscriminate of gender or ethnicity1. The 
incidence of the disease has increased in 
recent years and generally has a 10-year 
clearance rate in around 60% of children1. 
However, relapse can occur in later life, 
and for some it is a lifelong condition1. 
Leave-on emollients are emollients 
that are applied and left on the skin 
to alleviate symptoms such as dryness. 
These emollients are the mainstay of 
treatment for eczema, but adherence can 
be poor and is one of the main reasons 
for treatment failure2. Studies suggest that 
eczema patients report unwanted effects 
from leave-on emollients, which may 
contribute to adherence issues2. Reasons 
for this are multifactorial2,3,4 and are not 
fully understood. 
This paper will present the results of 
a study which focused on the unwanted 
effects of leave on-emollients, specifically 
looking at key aspects including: what 
unwanted effects patients may have 
Views on unwanted effects of 
leave-on emollients and experiences 
surrounding their incidence
experienced, issues that arose between 
the interaction of emollients and eczema 
treatment and what advice patients were 
given by healthcare professionals, what 
the reasoning was behind the actions 
patients took as a result and what they 
felt makes a good leave-on emollient. 
There is a breadth of information and 
data resulting from this study and this 
is why the emphasis of this paper will 
focus specifically on patient and carer 
experiences.  
Ethical considerations
The questionnaire that generated the 
data for this study was reviewed by the 
University of Nottingham’s School of 
Pharmacy Research Ethics Committee 
and given a favourable opinion (Ethics 
Reference No. 010-2016) before use.
Literature review
There are few formal reports on the 
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unwanted effects of leave-on emollients, 
how these may influence adherence and 
what wider implications this may have for 
total therapy. Despite patient reports2,3, 
unwanted events are poorly reported 
both in clinical practice5 and in trials 
of leave-on emollients6.  This suggests 
healthcare professionals are unaware of 
the range and impact of unwanted effects 
that eczema patients experience. 
The Medicines and Healthcare 
Products Regulatory Agency Drug 
Analysis Prints of all adverse event 
reports for common ingredients included 
within emollient medicinal products in 
the UK since 1963 suggest that very few 
reports of adverse events (such as skin 
reactions), following leave-on emollient 
application, have ever been made6. In 
addition, clinical trials involving leave-on 
emollients or moisturisers post year 2000 
showed that 27 (66%) did not mention 
any adverse events, either because the 
trials were not designed to report them or 
any adverse reactions encountered were 
not considered to have any significance6. 
These findings suggest that any adverse 
incident with leave-on emollients is 
generally disregarded by healthcare 
professionals. 
On the other hand, there is evidence 
that some emollients cause immediate 
cutaneous reactions7 and disturb 
important epidermal functions7,8,9. Such 
incidences contributed to the release of 
an MHRA report in 20139 which warned 
against the adverse events that had been 
reported with aqueous cream.
Aims and objectives
The aim of the study was to establish 
a deeper insight into the wider issues 
surrounding unwanted effects experienced 
with leave-on emollients. This was to be 
reported by, or on behalf of adults, young 
people and children with eczema. 
The study objectives were:
8 To compare the reports of unwanted 
effects of leave-on emollients from 
eczema patients and their support 
network
8 To establish the details of how 
unwanted effects may contribute to 
variations in emollient adherence
8 To gain a greater understanding of 
patients’ and carers’ (family members 
and friends) experiences of leave-on 
emollients
8 Understand what patients want from 
their leave-on emollients.
Methods
An anonymous online survey was 
conducted among eczema patients 
and their carers in March 2016 (using 
SurveyMonkeyTM). A questionnaire was 
developed by an expert group of 11 
healthcare professionals and patients to 
capture leave-on emollient experiences. 
The 20-question questionnaire was tested 
for content validity with this expert group 
(3 dermatologists, 2 eczema researchers, 
2 pharmacists, a general practitioner, 
a nurse, and 2 adult eczema patients). 
Categorical questions were organised into 
sections including demographics, previous 
history of treatments and experiences 
with leave-on emollients. Open questions 
were also asked for further clarification 
and opinions. Patients were contacted 
through online eczema support groups 
including the National Eczema Society and 
Nottingham Support Group for Carers 
of Children with Eczema via Twitter® and 
Facebook®. Analysis of the data collected 
in these questionnaires consisted of 
frequency counts and percentages. Open 
responses were thematically analysed and 
the patient and carer responses will be 
discussed within this paper.
Results
210 patients and their carers self-
selectively enrolled into the survey. 
Not all respondents completed the 
whole survey, therefore the number of 
respondents who responded to each 
question differs in reporting some results. 
The study is limited in its generalisability 
to the wider eczema community, as 
recruitment via support groups is likely 
to have resulted in responses relating to 
severe eczema patients.
Respondents all reported considerable 
levels of the same unwanted effects from 
the application of leave-on emollients. 
These unwanted effects were common, 
diverse in nature and stopped the use of 
some leave-on emollients, which further 
suggests that they have a role to play in 
adherence. 68% (n=126/185) of patients 
and/or carers responding on behalf of 
patients reported an unwanted effect 
due to a leave-on emollient10. Of these 
respondents, 71% (90/126) reported 
that they had stopped using a leave-on 
emollient due to unwanted effects and 
almost all (n=133/138, 96%) occurred 
when eczema was moderate to severe10 
as can be seen in Figure 1. Reports 
included a wide range of unwanted 
effects, with stinging being the most 
common (n=72/104, 69%), followed by 
greasiness that interfered with everyday 
life (n=50/104, 48%) and lack of efficacy 
(n=51/104, 49%)10. There were 38 
unwanted effects reported. 
Results of patient/carer questions relating to 
leave-on emollients
Unwanted effects question 
Within the last 3 years, have you or the 
















Clear Mild Moderate Severe
Results to the question: At the time you, or the person you are filling in this survey for, experienced the 
unwanted effect(s), how bad was the eczema? Severity scale adapted from reference 1.
 Figure 1
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experienced an unwanted effect (such as 
those listed below) when applying a leave-on 
emollient or moisturiser to treat symptoms of 
eczema? Unpleasant sensation (eg, itching, 
stinging, burning, tingling, feeling of hotness), 
a rash (reddening or darkening of skin), 
worsened eczema, cosmetic issues, odd smell 
or other problems?
68% (n=126/185) had experienced an 
unwanted effect from leave-on emollients, 
24% (n=45/185) had no experience 
and 8% (n=14/185) were unsure10. 
As seen in Table 1, the top 3 reactions 
experienced were the sensations felt on 
the skin: stinging, itching and burning. Other 
reactions related to a deterioration of the 
eczema and skin appearance following 
the application of the leave-on emollient. 
Patients, carers and relatives of all ages 
reported that if application of a product 
causes discomfort or does not improve 
the condition, then the default position 
is often to stop the product. Usually, 
alternatives may then be sought from a 
healthcare professional or retail outlets. 
NICE guidance (which is applicable 
to children under 12 years but could be 
generalised to young people and adults) 
could explain such behaviours as ‘not all 
types of emollients suit all people’ and 
‘children may have adverse reactions to 
some products, or may not like the way 
they feel on their skin’. However, there 
appears to be a misconception with the 
extent that unwanted effects are being 
experienced by patients in the literature. 
For example, best practice guidance 
highlights that ‘emollients are generally 
thought to be safe, with limited adverse 
effects’11. 
Licensed leave-on emollients for 
eczema are rigorously tested for quality, 
safety & efficacy12. However, toxicology 
studies exist for common ingredients 
within some emollients which mimic 
a selection of reported unwanted 
skin reactions10,13,14,15,16. Although such 
reactions are not dangerous, their 
nature suggests that some emollients 
could irritate or damage the skin7,8,9, 
which may exacerbate the eczema. 
However, interplay between ingredients 
in emollient formulations is also complex 
with potentially irritant properties of 
ingredients able to be mitigated by 
formulation design17. Therefore, such 
observations could be due to formulation 
approaches of specific products. Although, 
such stipulation requires further evidence 
and research for clarity.
The most commonly reported 
adverse reaction was stinging or 
discomfort on application and could 
be related to one or more of the 
constituents of the emollient and the 
severity of eczema10,13,14,15,16. Clinical 
experience suggests that such reactions 
are usually transient and could often be 
considered a normal response to an 
application of emollient. Whether such 
reactions are truly adverse or a reflection 
of other factors, such as eczema 
severity, requires further investigation. 
It is acknowledged that the relationship 
between the skin and an emollient is 
complex so the effects of emollients may 
not always be predictable11. However, 
the consensus is that regulator-approved 
emollients do not harm the skin barrier.
Child described (proprietary licensed 
emollient) and similar cream as “burning 
cream”.  
“Child gets very upset at the idea of cream, 
hates on hands (hands have really bad 
eczema), hates getting it on bed sheets, 
hates the feel of wearing cream next to 
clothes. Fear it will hurt going on due to bad 
experiences.”
“(Proprietary licensed) ointment was applied 
in a trial on my legs only. Within 10 minutes 
they were burning hot and had turned red. 
(Proprietary licensed) cream can only be 
applied just before bed in the knowledge it 
will be washed off in a shower the next day. If 
not washed off causes mild itching.”
Leave-on emollients are the mainstay 
of managing eczema1. National guidance 
advocates their use1 and other sources11 
also advise prescribing a small amount 
of emollient prescription to gauge the 
suitability for the patient. Upon looking at 
the skin reactions patients experienced, 
most could have potentially been 
avoided if guidance had been followed. 
By providing a selection of emollients to 
try, unsuccessful emollients could have 
been identified. Irritant and cosmetic 
acceptability considerations could then 
be investigated before prescribing and 
patients could be involved in the choice 
of product18. Further resources with 
open access available to healthcare 
professionals in relation to emollient 
prescribing include: Emollients, Potential 
Skin Sensitisers as Ingredients19 and 
The Electronic Medicines Compendium 
(eMC), where summaries of product 
characteristics for individual medicines 
can be searched. 
Patients’ experiences with leave-on emollients
“A nurse practitioner at the dermatology 
department I was referred to noted that my 
experiences mirrored that of several of their 
patients and suggested that I might benefit 
from periodic rotation through a roster of 
products.”
Cosmetic issues and product choice 
are also important considerations for 
patients and will affect adherence. Within 
this study the main aspects highlighted in 
Table 2 were: greasiness that interfered 
with everyday life, feeling hot, tacky and 
sticky sensations, stained clothing and 
ReseaRch STUDY
Table 1.
Frequency of skin reactions reported by 







39 38% worsened eczema
33 32% worsened a rash
29 28% reddening or darkening of the skin
25 24% tingling
22 21% swelling or inflammation




3 3% none of these
1 1% patient reported allergic reaction
1 1% hives
1 1% red bumps (infected hair follicle)
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shiny skin. Such reports appeared to be 
attributed to, not just one product, but: 
most available UK proprietary leave-on 
emollients licensed for eczema, unlicensed 
UK emollients which may be registered 
as a medical device, an approved UK 
Advisory Committee on Borderline 
Substances (ACBS) substance or a 
cosmetic. 
“Hot behind knees, which closed pores, 
sweating then severe itching.”
“It shouldn’t leave any residue. Sometimes 
after I get a bit warm, the area the 
emollient was applied to feels really wet — 
I don’t like this.” 
 
As can be seen in Table 3, other issues 
highlighted within the study related to the 
clinical effect and the refusal by children 
to have the products applied to the skin, 
which may confirm that unwanted effects 
from leave-on emollients do contribute 
to poor adherence as suggested in 
previous papers2,3. This may be related 
to a behavioural component in children, 
but as previous papers have confirmed2 
this is usually due to stinging sensations. 
Similar to the findings of this study, families 
within previous studies2,3 reported 
employing a range of strategies, which 
included involving the child in treatment, 
distracting the child during treatment, 
or making a game of it, using rewards, 
applying treatment to a sleeping child 
or, in a few cases, physically restraining 
the child. However, carers in this study 
also reduced the frequency of treatment 
applications2, which could result in 
suboptimal therapy. 
Poor treatment adherence, leads 
to ‘cream wars’ with battles between 
the patient, family and medical team 
over the consistent use of prescribed 
creams. Stories about eczema can 
help and a recent study developed 
personalised stories as a technique to 
improve treatment adherence, reduce 
stigma and facilitate effective adult-child 
communication20. To facilitate better 
communication with children about 
their eczema, Nottingham University 
has produced story books. These stories 
can be used by parents and healthcare 
professionals and can be personalised 
for a child. Two stories introduce ideas 
to help break the itch-scratch cycle and 
two are targeted at improving treatment 
adherence.  They are available from The 
Centre of Evidence Based Dermatology, 
Nottingham University. Visit www.
nottingham.ac.uk/research/groups/cebd/
resources/psychology-and-eczema.aspx 
to read and learn from these different 
experiences.
“We currently use (a proprietary licensed 
emollient) as the main emollient on our 
16-month old son, but it’s very slippy! We 
can’t put it on when he’s on the changing unit, 
has to be done sat on the floor because if 
he slips/tries to get away (usually!!) then we 
wouldn’t be able to grip him to catch him!” 
Stopping the leave-on emollient question 
Was the unwanted effect(s) for you or the 
person you are filling in this survey for, bad 
enough for you, or them, to stop using the 
leave-on emollient or moisturiser that caused 
the unwanted effect(s)?
71% (90/126) of patients stopped 
leave-on emollients due to unwanted 
effects10. Leave-on emollients are stopped 
by patients and carers for several reasons. 
Commonly it is because of the adverse 
effect or because the eczema has cleared 
and they have not understood the 
importance of continuing the use. Some 
patients made the decision independently 
while others sought healthcare 
professional advice.
     
“She wants to but I keep having her use it.”
“I have had these episodes before and was 
told by the doctor to persevere with the 
moisturisers.”
“Baby was in pain but doctors said we had 
to do it.”
“I stopped using it for a little bit but realised 
this happened when I first started using a 
cream. After getting used to the cream it 
would happen less often.” 
Use with other products
Within the last 3 years, have you or the 
person you are filling in this survey for 
ever applied a leave-on emollient or 
moisturiser to the same bit of eczematous 
skin immediately following or followed by 
another product and ever applied leave-on 
emollients or moisturisers under: bandages, 
gloves, wet/dry wraps, or other therapeutic 
material?
Patients and carers were also asked 
about the use of leave-on emollients 
with other products. National guidance 
advises that when emollients (excluding 
bath emollients) and other topical 
products are used at the same time 
of day, the different products should 
Table 2.
Frequency of cosmetic issues reported by 





greasiness that interfered with 
everyday life
38 37% feeling of hotness
29 28% tacky feeling on the skin
27 26% stickiness
26 25% stained clothes
24 23% shininess
23 22% none of these
12 12% blocked pores
8 8% feeling cold or clammy
1 1%
failure of product to remove when 
washing
Table 3.




% Other unwanted effects
51 49% it didn't work
31 30% child refused application
22 21% none of these
20 19% off-putting smell
19 18% slipping when gripping objects
12 12% infection
3 3% phobia of leave-on emollient
1 1% upset child
1 1% sweating, leading to itching
ideally be applied one at a time with 
several minutes between applications 
where practical1. The preferences of 
the child and parents or carers should 
determine which product should be 
applied first, leaving a gap (of several 
minutes) between emollient products 
and topical corticosteroids (TCS)1. The 
evidence for emollient or TCS applied first 
is inconclusive, but according to a recent 
study the order of application of emollient 
and TCS does not matter in the treatment 
of atopic eczema in children21. Parents 
can also apply topical medications in 
whichever order they prefer21, which may 
contribute to patient adherence. However, 
60% (82/136) had used emollients with 
TCS and some had mixed TCS or TCS 
and antibiotic combinations.  For some 
topical calcineurin inhibitors (TCI) such as 
Protopic® ointment, patients are advised 
to leave a 2-hour gap between the two 
applications22,23. Despite this guidance, 
19% (26/136) had used TCIs with 
emollients and of these respondents 77% 
(17/22) experienced burning sensations 
compared with 56% (58/104) of all other 
respondents. TCIs are known to have 
burning sensations as listed side effects22,23, 
which suggests that such reports could 
be attributed to either the emollient or 
mixing with the TCI19,22,23,24.
“I have used different moisturisers such as 
(proprietary licensed emollient) and cocoa 
butter and (proprietary licensed emollient) 
and if skin is breaking I use (proprietary 
unlicensed anitiseptic) on top covered too or 
steroid cream.”
“(Proprietary licensed calcineurin inhibitor) 
then basic aqueous cream or (proprietary 
unlicensed emollient).”
49% (93/188) had also applied 
emollients under bandages, gloves, wet/
dry wraps, or other therapeutic material. 
Interestingly, these respondents reported 
experiencing a greater proportion of all 
the reported types of unwanted effects; 
with 80% (74/93) describing unwanted 
effects with leave-on emollient use 
compared to 68% (126/185) of all other 
respondents.
Homemade emollients 
“We use shea butter or a homemade 
mixture of shea butter + coconut oil + 
cocoa butter.”
“Oil-based cream with olive sunflower and 
rapeseed oils mixed with aqueous.”
The mixing and creation of 
therapeutic products plus the use of 
therapeutic material with emollients 
could suggest that patients find it difficult 
to manage their condition with current 
treatments. However, this behaviour may 
be unsafe because such formulations may 
be liable to microbial contamination12 and 
may exacerbate eczema17 due to a lack 
of formulator knowledge and ingredients 
that haven’t undergone stringent quality 
control measures8,12,17.
Natural emollients 
“Natural moisturisers and oils such as raw 
coconut, shea butter, olive oil, cocoa butter, 
mango butter, Vaseline®.”
It was observed that 5% (10/193) 
of respondents used natural oils and 
moisturisers as a form of emollient 
therapy. This trend may emerge from 
personal beliefs that may have arisen from 
negative experiences with preparations or 
marketing strategies.
However, research has highlighted 
that some natural oils, such as olive oil, 
significantly damage the skin barrier and 
may exacerbate eczema25. Therefore 
healthcare professionals should be vigilant 
of such practices and recommendations 
should be made on the best available 
evidence.
What makes a good leave-on emollient? 
The Eczema Priority Setting Partnership 
found that identifying the most effective 
and safe emollients was a top priority 
shared by patients and healthcare 
professionals26. It was addressed within 
this study by asking what makes a good 
leave-on emollient or moisturiser. This 
answer elicited a wealth of suggestions, 
which at times were contradictory. The 
main themes from the open responses 
focused on: 
8 Consistency
8 Non-greasy, easily absorbed, thick 
moisturiser. Lotions are often thin and 
have to be reapplied to be effective
8 A well-balanced moisturiser with grease 
and cream
8 Something that isn’t too oily
8 I also much prefer a more ‘natural’ 
emollient wherever possible (just natural 
oils, etc, rather than petroleum derived). 
The reality is that the natural ones 
available over the counter aren’t as good 
as the prescribed ones.
8 Frequency of application 
8 One product lasts a long time
8 During the day I want something that 
absorbs quickly so I don’t have to feel 
self conscious walking around — I hate 
it when it stays on your skin and sticks to 
clothes. For overnight treatments I think 
the thicker the better so it absorbs slowly 
and you can feel it working
8 Not sticky, dries quickly, portable, easy to 
apply, gives long lasting relief.
8 Minimising adverse effects 
8 A moisturiser that removes the stinging 
sensation from my eczema
8 Thick and oily as less painful
8 Seems hit and miss as to whether she will 
react to the cream
8 One that doesn’t make it worse. SLS 
appears to increase itching... 
8 One that doesn’t make me itch more 
8 Cosmetically acceptable 
8 No odour, non-greasy, one that sticks but 
doesn’t grease up and stain clothing/
bedding
8 One that is deeply moisturising and soaks 
into the skin easy without leaving greasy 
residue on the skin surface.
8Adherence
8 Something which the person is 
comfortable to have applied and leave on, 
eg, my child was using creams but hated 
to be touched so was switched 
to spray
8 How well it ‘sticks’. Small children roll 
about, scratch, wipe and wriggle and 
some of the thinner emollients just don’t 
stay put (especially if, for example, you’re 
battling to get pyjamas on).
8 Other comments 
8 Its effectiveness. They are all different, it 
depends on the part of cycle you are in 
or what time of day/night and season.
Implications for practice
This study and the patient-focused 
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questions discussed in this paper have 
highlighted that unwanted effects from 
leave-on emollients are commonly 
reported by patients, are diverse in nature, 
have an impact on adherence, and may 
be associated with the severity of eczema 
and the type of leave-on emollients used10. 
Unwanted effects need to be considered 
when optimising therapy for patients. 
Education and support for eczema patients 
in all care settings should be consistent; 
with a focus on the types of emollient 
product being used (either prescribed or 
purchased), how they are being applied, 
their use or mixing with other topical 
therapies and asking about any unwanted 
effects. If unwanted effects are an issue, 
providing a choice of products will help 
patients find a product that is right for 
them, which will improve adherence and 
quality of life for patients.
Conclusion
Eczema patients and their carers all 
reported high levels of unwanted effects 
from leave-on emollient use. Experiences 
of unwanted effects were multifactorial but 
common themes arose, as did the desire 
for emollient improvements. The reason 
why unwanted effects occur is still unclear, 
requiring further investigation and more 
robust adverse event reporting.
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